Vectus Biosystems

Vectus Biosystems Inventory Turnover

The Inventory Turnover Ratio of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 14.00. In the previous year, Inventory Turnover Ratio was 60.16 — a change of -76.73% (lower).

Inventory Turnover

14.00

YoY

-76.73%

Last updated:

Inventory Turnover Ratio of Vectus Biosystems is 2025 14.00 . Inventory Turnover Ratio of Vectus Biosystems was 2024 60.16 . It decreases by -76.73% lower compared to the previous year.

The Vectus Biosystems Inventory Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory Turnover
Date
Inventory Turnover
Jan 1, 2018
-0.79 AUD
Jan 1, 2019
-0.72 AUD
Jan 1, 2020
0.42 AUD
Jan 1, 2021
-1.23 AUD
Jan 1, 2022
51.11 AUD
Jan 1, 2023
48.27 AUD
Jan 1, 2024
60.16 AUD
Jan 1, 2025
14.00 AUD
The Vectus Biosystems Inventory Turnover history
YEARInventory TurnoverYoY
14.00-76.73%
60.16+24.63%
48.27-5.56%
51.11-4,254.14%
-1.23-389.73%
0.42-159.19%
-0.72-9.05%
-0.79+32.20%
-0.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Inventory Turnover Ratio of Vectus Biosystems is 14.00 in 2025.

Inventory Turnover Ratio of Vectus Biosystems changed from 60.16 to 14.00, representing a -76.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Turnover Ratio Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Inventory turnover measures how many times inventory is sold and replaced during a period. Higher turnover indicates efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory Turnover Ratio's Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Vectus Biosystems

All Key Metrics — Vectus Biosystems